Table 3 SRR (95% CI) of the risk of subsequent cancers in patients exposed to group I pharmaceuticals by indication.

Cyclosporine

Skin

Solid organ transplant

11^{20,21,22,23,24,25,26,27,28,30,31}

1.17 (0.98–1.40)ⁱ

Rheumatoid arthritis

2^29,32

3.55 (1.60–7.85)ⁱ

Hematologic

Solid organ transplant

6^{20,33,34,35,36,37}

0.96 (0.86–1.07)^l

Azathioprine

Skin

Solid organ transplant

8^{21,22,23,24,25,27,28,31}

1.43 (1.11–1.83)ⁱ

Inflammatory bowel disease

3 ^38,40,41

1.63 (0.99–2.66)^l

Myasthenia

1³⁹

3.30 (1.50–7.30)

Rheumatoid arthritis

1²⁹

1.94 (0.87–4.34)

Hematologic

Solid organ transplant

7^{33,34,35,36,37,46,47}

1.08 (0.81–1.45)^h

Inflammatory bowel disease

3^38,42,45

3.77 (2.56–5.54)^l

Rheumatoid arthritis

1⁴³

1.07 (0.74–1.54)

Systemic lupus erythematosus

1⁴⁴

1.19(0.48–2.92)

Cyclophosphamide

Bladder

Non-Hodgkin lymphoma

2^49,50

2.31 (0.58–9.24)ⁱ

Ovarian cancer

1⁴⁸

4.20 (1.20–14.00)

Hematologic

Non-Hodgkin lymphoma

2^50,54

1.59 (0.71–3.55)^l

Breast cancer

1⁵¹

3.10 (1.30–7.70)

Lymphoma

1⁵³

14.80 (3.70–59.4)

Rheumatoid arthritis

1⁴³

1.84 (1.24–2.73)

Ovarian cancer

1⁵²

2.65 (1.64–4.26)

Systemic lupus erythematosus

1⁴⁴

2.09 (0.69–6.30)

Busulfan

Hematologic

Essential thrombocythemia

1⁵⁵

4.48 (1.11–27.10)

Polycythemia vera

1⁵⁶

8.64 (2.44–30.60)

Chlorambucil

Hematologic

Non-Hodgkin lymphoma

1⁵⁴

2.40 (0.70–8.60)

Ovarian cancer

1⁵²

1.19 (0.72–1.97)

Methoxsalen + UV

Skin

Psoriasis

1⁵⁷

6.50 (1.40–31.40)

Melphalan

Hematologic

Breast cancer

1⁵¹

3.10 (1.30–7.70)

Ovarian cancer

2^52,58

5.83 (0.55–61.2)^h

MOPP

Lung

Hodgkin disease

1⁵⁹

5.00 (2.10–13.60)

Etoposide

Hematologic

Solid tumor

1⁶⁰

2.70 (1.20–6.00)

Thiotepa

Hematologic

Ovarian cancer

1⁵²

1.82 (1.09–3.03)